Autologous stem cell transplantation in autoimmune and rheumatic diseases: From the molecular background to clinical applications

Scandinavian Journal of Rheumatology

Volumn 39, Issue 1, 2010, Pages 1-11

  Szodoray, P ^a,b   Varoczy, L ^b   Szegedi, G ^a   Zeher, M ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; GLATIRAMER; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BEHCET DISEASE; CD34 SELECTION; CRYOGLOBULINEMIA; DERMATOMYOSITIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; HODGKIN DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; JUVENILE RHEUMATOID ARTHRITIS; MIXED CONNECTIVE TISSUE DISEASE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; POLYMYOSITIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS; WHOLE BODY RADIATION;

ANIMALS; ANTIGENS, CD34; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MOLECULAR BIOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATIC DISEASES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 76749137609     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903030324     Document Type: Review

References (71)

1. Davidson A, Diamond B. General features of autoimmune disease. In: Rose NR, Mackay IR, editors. The autoimmune diseases, 4th edn. Oxford, UK: Elsevier Academic Press; 2006. p. 25-36.
2. Cooper GS, Miller FW, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect 1999;/107(Suppl 5):/693-700.
3. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature 2005;/435:/620-7.
4. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006;/54:/3750-60.
5. Pavletic SZ. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for autoimmune disease. Arthritis Rheum 2004;/50:/2387-90.
6. Van Laar JM, Tyndall A. Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control 2003;/10:/57-65.
7. Gratwohl A. Allogeneic hematopoietic stem cell transplantation for severe autoimmune diseases. Autoimmunity 2008 Oct 28:1. DOI: 10.1080/08916930802197677
8. Beilhack GF, Scheffold YC,Weissman IL, Taylor C, Jerabek L, Burge MJ, et al. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 2003;/52:/59-68.
9. Salomon BL, Sudres M, Cohen JL. Regulatory T cells in graftversus- host disease. Springer Semin Immunopathol 2006;/28:/25-9.
10. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005;/201:/805-16.
11. Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996;/156:/4609-16.
12. Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17- Th cells that cause autoimmune arthritis. J Exp Med 2007;/204:/41-7.
13. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD25- CD4- T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001;/166:/3008-18.
14. Hagen KA, Moses CT, Drasler EF, Podetz-Pedersen KM, Jameson SC, Khoruts A. A role of CD28 in lymphopeniainduced proliferation of CD4 T cells. J Immunol 2004;/173:/ 3909-15.
15. Herrmann MM, Gaertner S, Stadelmann C, van den Brandt J, Böscke R, Budach W, et al. Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood 2005;/106:/1875-83.
16. de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Yung GP, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4-CD25- immune regulatory network. Blood 2006;/107:/ 1696-702.
17. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature 2005;/435:/620-7.
18. Tyndall A, Leblanc K. Stem cells and rheumatology: update on adult stem cell therapy in autoimmune diseases. Arthritis Rheum 2006;/55:/521-5.
19. Van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006;/45:/1187-93.
20. Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007;/20:/349-60.
21. Laustrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8- year prospective study. Scand J Rheumatol 2009;/38:/128-32.
22. Mok CC, Ho LY, Cheung MY, Yu KL, To CH. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009;/38:/121-7.
23. Svenungsson E, Cederholm A, Jensen-Urstad K, Fei GZ, de Faire U, Frostegård J. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand J Rheumatol 2008;/37:/ 352-9.
24. Jayne D. Stem cell transplantation in systemic lupus erythematosus. Best Pract Res Clin Haematol 2004;/17:/291-304. (Pubitemid 39145100)
25. de Buys P, Khanna D, Furst DE. Hemopoietic stem cell transplantation in rheumatic diseases- an update. Autoimmun Rev 2005;/4:/442-9.
26. Burt RK, Traynor A, Statkute L, BarrWG, Rosa R, Schroeder J, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. J Am Med Assoc 2006;/295:/527-35.
27. Illei GG, Pavletic SZ. Blood stem cells as therapy for severe lupus. Expert Opin Biol Ther 2005;/5:/1153-64.
28. Pavletic SZ, Illei GG. The role of immune ablation and stem cell transplantation in severe SLE. Best Pract Res Clin Rheumatol 2005;/19:/869-58
29. Marmont AM, Burt RK. Hematopoietic stem cell transplantation for systemic lupus erythematosus, the antiphospholipid syndrome and bullous skin diseases. Autoimmunity 2008 Oct 28:1. DOI: 10.1080/08916930802197677
30. Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 2000;/356:/ 701-7.
31. Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, et al. European Group for Blood and Marrow Transplantation; European League Against Rheumatism Registry. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004;/13:/168-76. (Pubitemid 38478643)
32. Illei GG. Hematopoietic stem cell transplantation in autoimmune diseases: is the glass half full or half empty? Arthritis Rheum 2006;/54:/3730-4.
33. Karim MY, Pisoni CN, Khamashta MA. Update on immunotherapy for systemic lupus erythematosus- what's hot and what's not! Rheumatology (Oxford) 2009;/48:/332-41.
34. Hügle T, van Laar JM. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther 2008;/10:/217.
35. Scheja A, Bartosik I, Wuttge DM, Hesselstrand R. Renal function is mostly preserved in patients with systemic sclerosis. Scand J Rheumatol 2009 Feb 11:1-4. DOI: 10.1080/ 03009740802629424
36. Kampolis C, Plastiras S, Vlachoyiannopoulos P, Moyssakis I, Tzelepis G. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol 2008;/37:/ 278-83.
37. Farge D, Henegar C, Carmagnat M, Daneshpouy M, Marjanovic Z, Rabian C, et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 2005;/52:/1555-63.
38. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, et al. EBMT/EULAR Registry. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;/63:/ 974-81.
39. Nikolov NP, Pavletic SZ. Technology Insight: hematopoietic stem cell transplantation for systemic rheumatic disease. Nat Clin Pract Rheumatol 2008;/4:/184-91.
40. van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005;/64:/1515.
41. Tyndall A, Furst DE. Adult stem cell treatment of scleroderma. Curr Opin Rheumatol 2007;/19:/604-10.
42. van Laar JM, Farge D, Tyndall A. Stem cell transplantation: a treatment option for severe systemic sclerosis? Ann Rheum Dis 2008;67(Suppl 3):iii35-iii38.
43. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Autologous stem cell transplantation in progressive multiple sclerosis- an interim analysis of efficacy. J Clin Immunol 2000;/20:/24-30.
44. Su L, Xu J, Ji BX, Wan SG, Lu CY, Dong HQ, et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006;/84:/276-81.
45. Kozak T, Havrdova E, Pit'ha J, Gregora E, Pytlík R, Maaloufova J, et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000;25:525-31.
46. Mancardi G, Saccardi R. Autologous haematopoietic stem cell transplantation in multiple sclerosis. Lancet Neurol 2008;/7:/ 626-36.
47. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005;/105:/2601-7.
48. Saiz A, Blanco Y, Carreras E, Berenguer J, Rovira M, Pujol T, et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 2004;/62:/ 282-4.
49. Mancardi GL. Autologous Stem-cell Transplantation International MS trial. EudraCT number 2007-000064-124 Available online at: www.astims.org (accessed 29 May 2008).
50. Bowen J. High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study. Available online at: http://clinicaltrials. gov/ct2/show/ NCT00288626.
51. Carli C, Bridges JF, Ask J, Lindblad S. Swedish Rheumatoid Arthritis Register. Charting the possible impact of national guidelines on the management of rheumatoid arthritis. Scand J Rheumatol 2008;/37:/188-93.
52. Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar J, et al. Autologous hematopoietic stem cell transplantation in severe rheumatoid arthritis. J. Rheumatol 2004;/31:/ 482-8.
53. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol 2005;/141:/1-9.
54. Verburg RJ, Kruize AA, van den Hoogen FH, Fibbe WE, Petersen EJ, Preijers F, et al. High dose chemotherapy and autologous stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety and efficacy. Arthritis Rheum 2001;/44:/754-60.
55. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002;/46:/2301-9.
56. Passweg J, Tyndall A. Autologous stem cell transplantation in autoimmune diseases. Semin Hematol 2007;/44:/278-85.
57. Verburg RJ, Flierman R, Sont JK, Ponchel F, van Dreunen L, Levarht EW, et al. Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Ann Rheum Dis 2005;/64:/1397-405.
58. Teng YK, Verburg RJ, Sont JK, van den Hout WB, Breedveld FC, van Laar JM. Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. Arthritis Rheum 2005;/52:/2272-6.
59. Barron KS, Wallace C, Woolfrey CEA, Laxer RM, Hirsch R, Horwitz M, et al. Autologous stem cell transplantation for pediatric rheumatic diseases. J Rheumatol 2001;/28:/2337-58.
60. Wulffraat NM, de Kleer IM, Prakken BJ, Kuis W. Stem cell transplantation for autoimmune disorders. Refractory juvenile idiopathic arthritis. Best Pract Res Clin Haematol 2004;/17:/ 277-89.
61. Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2006;/20:/279-300.
62. Miltenyi S. CD34- selection: the basic component for graft engineering. Oncologist 1997;/2:/410-3.
63. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 2003;/42:/375-9.
64. Verda L, Oyama Y, Craig R, Statkute L, Krosnjar N, Quigley K, et al. Restoration of the CD4-CD25bright regulatory cell subset in patients with Crohn's disease following autologous non-myeloablative stem cell transplantation (NST). Blood 2005;106:Abstract 2193.
65. Váróczy L, Illés A, Kiss E, Szekanecz Z, Soltész P, Sipka S, et al. High-dose chemotherapy followed by autologous CD34- stem cell transplantation in the treatment of severe refractory multisystem autoimmune diseases of adults- first experiences in Hungary. Orv Hetil 2008;/149:/1405-12.
66. Zeher M, Szegedi G. The treatment of autoimmune patients with autologous stem cell transplantation. Lege Artis Medicinae 2007;17:853-8.
67. de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Yung GP, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4- CD25- immune regulatory network. Blood 2006;/107:/1696-702.
68. Braun-Moscivivi Y, Furst DE. Stem cell therapy in scleroderma. Curr Opin Rheumatol 2002;/14:/711-6.
69. Bohgaki T, Atsumi T, Koike T. Autoimmune disease after autologous hematopoietic stem cell transplantation. Autoimmun Rev 2008;/7:/198-203.
70. Imamura R, Inoue H, Kato K, Kobayashi S, Tsukamoto H, Nagafuji K, et al. Development of rheumatoid arthritis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;/30:/527-9.
71. Müller I, Lymperi S, Dazzi F. Mesenchymal stem cell therapy for degenerative inflammatory disorders. Curr Opin Organ Transplant 2008;/13:/639-44.